- Home
- ZIP vs LXEO Comparison
ZIP vs LXEO Comparison
Compare ZIP & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZIP
- LXEO
- Stock Information
- Founded
- ZIP 2010
- LXEO 2017
- Country
- ZIP United States
- LXEO United States
- Employees
- ZIP N/A
- LXEO N/A
- Industry
- ZIP Diversified Commercial Services
- LXEO
- Sector
- ZIP Consumer Discretionary
- LXEO
- Exchange
- ZIP Nasdaq
- LXEO Nasdaq
- Market Cap
- ZIP 336.8M
- LXEO 290.5M
- IPO Year
- ZIP 2021
- LXEO 2023
- Fundamental
- Price
- ZIP $4.48
- LXEO $9.14
- Analyst Decision
- ZIP Hold
- LXEO Strong Buy
- Analyst Count
- ZIP 4
- LXEO 8
- Target Price
- ZIP $4.75
- LXEO $18.13
- AVG Volume (30 Days)
- ZIP 959.3K
- LXEO 1.4M
- Earning Date
- ZIP 11-05-2025
- LXEO 11-12-2025
- Dividend Yield
- ZIP N/A
- LXEO N/A
- EPS Growth
- ZIP N/A
- LXEO N/A
- EPS
- ZIP N/A
- LXEO N/A
- Revenue
- ZIP $450,401,000.00
- LXEO N/A
- Revenue This Year
- ZIP N/A
- LXEO N/A
- Revenue Next Year
- ZIP $9.96
- LXEO N/A
- P/E Ratio
- ZIP N/A
- LXEO N/A
- Revenue Growth
- ZIP N/A
- LXEO N/A
- 52 Week Low
- ZIP $3.35
- LXEO $1.45
- 52 Week High
- ZIP $11.25
- LXEO $11.72
- Technical
- Relative Strength Index (RSI)
- ZIP 52.12
- LXEO 69.97
- Support Level
- ZIP $4.27
- LXEO $8.50
- Resistance Level
- ZIP $4.64
- LXEO $8.88
- Average True Range (ATR)
- ZIP 0.24
- LXEO 0.65
- MACD
- ZIP 0.06
- LXEO 0.09
- Stochastic Oscillator
- ZIP 81.46
- LXEO 75.77
About ZIP ZipRecruiter Inc.
ZipRecruiter Inc is an online employment marketplace. It connects millions of job seekers with companies of all sizes. It is a two-sided marketplace for work that simplifies the job market for both job seekers and employers. Unlike traditional online job sites, ZipRecruiter works like a matchmaker curating job opportunities for job seekers, and candidates for employers.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.